Spectrum Pharma (SPPI) Misses Q4 EPS by 7c

March 30, 2021 4:03 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Spectrum Pharma (NASDAQ: SPPI) reported Q4 EPS of ($0.36), $0.07 worse than the analyst estimate of ($0.29).

“The Fast Track designation for poziotinib is a significant achievement towards an expedited review,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “In addition, we are delighted that the FDA has scheduled the pre-approval inspection at the ROLONTIS manufacturing facility for May 2021. The company has made tremendous progress advancing our development programs and conducting our clinical trials, despite the challenges of the global pandemic. I am proud of our employees who demonstrated resiliency and creativity during these unprecedented times.”

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Management Comments

Related Entities

Earnings, FDA